A Blog About Intellectual Property Litigation and the District of Delaware


RGA
The Honorable Richard G. Andrews

Judge Andrews: No Broad Rule 30(b)(6) Deposition Before Preliminary Injunction Hearing

Andrew E. Russell, Jan. 24, 2022
Preliminary Injunction Discovery

Bay Materials, LLC v. 3M Company, C.A. No. 21-1610-RGA (D. Del.) is a competitor patent infringement case where a smaller company is trying to prevent a larger competitor—3M—from allegedly copying its "flagship product," a "multilayer polymer sheet material" called "Zendura™ FLX."

The plaintiff moved for a preliminary injunction immediately upon filing the case, and the parties filed a stipulation agreeing to a discovery and briefing schedule. The parties disputed whether the defendant should be able to take an FRCP 30(b)(6) deposition of the plaintiff as part of the preliminary injunction discovery.

Defendant sought the 15-topic FRCP 30(b)(6) deposition to prevent plaintiffs' witnesses from "claim[ing] a lack of knowledge about relevant topics." Plaintiff argued that the notice was …

View

Court Issues Permanent Injunction, Sidesteps Need for Analysis: "It Is Regrettable That the Parties Could Not Resolve This Without Me"

Andrew E. Russell, Jan. 14, 2022
Post-Trial Relief Congestion

Pipeline
Mike Benna, Unsplash

Judge Andrews resolved a request for a permanent injunction in a patent case today, in a way I haven't seen before.

In Sunoco Partners Marketing & Terminals L.P. v. Powder Springs Logistics, LLC, C.A. No. 17-1390-RGA (D. Del.), the plaintiff won an infringement jury verdict in a trial last month.

The patents involve mixing gasoline with butane automatically, rather than through a process that involves manual intervention. The accused infringement involves the mixing of gasoline and butane on a pipeline.

Plaintiff immediately moved for a permanent injunction, and sought a hearing on the injunction on December 22 or 23, just before the holidays. The patent relevant to the permanent injunction expires in April …

View

Skinny Labels Are Back, Baby

Nathan R. Hoeschen, Jan. 6, 2022
ANDA Labels

On Tuesday, Judge Andrews issued what I believe is the first opinion in the district regarding "skinny labels" since the Federal Circuit issued its decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021).

As anyone immersed enough in patent law to read this blog will know, skinny labeling is the practice of excluding certain indications from the generic drug's label and associated inserts, so as to avoid inducing infringement of method of treatment patents listed in the orange book. In Amarin Pharma, Inc. et al v. Hikma Pharmaceuticals USA Inc., C.A. No. 20-1630-RGA, D.I. 97 (D. Del. Jan. 4, 2022), for instance, the branded drug was indicated for treatment of severe …

View

Is Receipt of a Letter Listing Only the Patent and Accused Product Enough to State a Claim for Willfulness?

Andrew E. Russell, Jan. 5, 2022
Willfulness MTD

Envelope with Letter
Brando Makes Branding, Unsplash

That is the question Judge Andrews addressed yesterday. He found that yes, a letter listing a patent and accused product is enough to state a claim in a complaint for pre-suit willfulness—the letter need not include things like claim charts or specific descriptions of product features:

I find that the notice letter sufficiently pleads knowledge for the eight patents-in-suit listed in the letter. The letter lists many LG products and states, " These products, and others made, used, sold, offered for sale, or imported into the United States by LG, infringe many of the patents in [Bench Walk's] portfolio." (D.I. 25-1 at 1-2). The letter then enumerates eleven patents, including eight of the ten …
View

Judge Andrews Awards Fees for Continued Assertion of Baseless Infringement Claims

Jeff Castellano, Jan. 4, 2022
Attorney's Fees

One of the questions Courts have to answer when presented with an application for attorneys' fees under 35 U.S.C. § 285 is when to start the clock running on fees. The analysis can include objective and subjective factors, but in general (in this District at least) a patentee has to push through multiple warning signs and opportunities for reevaluation before its continued assertion of infringement will justify an award of fees.

Earlier this week, Judge Andrews awarded fees for plaintiffs' continued assertion of infringement after (1) an adverse claim construction decision and (2) subsequent notice from the defendant of non-infringement. After the Court granted summary judgment of non-infringement, the defendant moved for fees.

Judge Andrews quickly disposed with the …

View

Judge Andrews Sua Sponte Limits Number of Slides for Summary Judgment and Daubert Argument; a First?

Andrew E. Russell, Dec. 27, 2021
Case Management Congestion

I wonder when slides like these were last used in district court?
I wonder when slides like these were last used in district court? Jo Gala, Unsplash

Last week, in First Quality Tissue, LLC v. Irving Consumer Products Limited, C.A. No. 19-428-RGA (D. Del.), Judge Andrews issued the following order, apparently sua sponte:

ORAL ORDER: In connection with the argument currently scheduled for January 19, 2022 [regarding pending Daubert and summary judgment motions], the parties shall submit non-argumentative letters by January 4, 2022, specifying, in order of importance to the party, the issues they want to argue, with citations to where the relevant briefing can be found. The parties should not specify more than three issues each. At the argument, the total page limit for each sides …
View

Court Permits Early Summary Judgment Motion After Parties Consent to Magistrate Judge Jurisdiction

Andrew E. Russell, Dec. 26, 2021
Early SJ Summary Judgment

Last month we wrote about Chief Judge Connolly's comments on the "sad reality" of referrals of SJ motions to a magistrate judge in patent cases:

[T]he sad reality in patent cases filed in this district is that a referral of a summary judgment motion [for an R&R] pursuant to § 636(b)(l)(B) inevitably results in objections to the magistrate judge's report and recommendation, which the district court judge must review de novo. Such a referral therefore ends up doubling the amount of judicial resources needed to resolve the summary judgment motion in question. For that reason, I no longer make § 636(b)(l)(B) referrals of summary judgment motions in patent cases to a magistrate judge.

He noted at the time …

View

What You Say in Prosecution Can Be Used Against You, Even if the Examiner Disagrees

Jeff Castellano, Dec. 21, 2021
Claim Construction

In a recent order, issued shortly after the Markman hearing in Allergan USA, Inc. v. Aurobindo Pharma Ltd., C.A. No. 19-1727-RGA, Judge Andrews addressed the question of "how much weight should be assigned to a Patent Examiner's statement, in a Notice of Allowance, about the meaning of a claim."

He explained the background as follows:

During prosecution of the '291 Patent, Plaintiffs initially argued that the claimed percentage of mannitol, a well-known filler, should be calculated separately from the claimed percentage of filler. The Examiner disagreed, and, in his Notice of Allowance, indicated that the percentage of mannitol would be included in calculating the percentage of filler.

(emphasis added)

The plaintiffs/patentees urged the Court to ignore their initial statements and arguments, and instead adopt the Examiner's position. Judge Andrews declined to do so...

View

Judge Andrews Declines to Adopt Proposed Constructions, Construes Term as Plain Meaning

Andrew E. Russell, Nov. 29, 2021
Plain Meaning

At a claim construction hearing the week before last, Chief Judge Connolly discussed the pitfalls of a party proposing "plain meaning" as a construction without specifying what the plain meaning is, and how that may just end up deferring disputes until later in the case. We'll have a post about that once the transcript is available.

In the meantime, I thought it was interesting that Judge Andrews this month declined to adopt opposing proposed constructions from the parties in an action, and construed the term as "plain and ordinary meaning":

Plaintiffs expert Dr. Robert Ruffolo asserts that a person of ordinary skill in the art would have understood the term "pharmaceutical batch" to incorporate [a] regulatory definition . . . …
View

The Beginning of the End for Remote Depositions?

Nathan R. Hoeschen, Nov. 21, 2021
Remote Depositions

Plane in Turbulence
Turbulence, Joshua Hoehne, Unsplash

Perhaps the most facile musing of the late-stage (please) pandemic, is wondering if remote work will become a permanent fixture in our lives. It's become such a common topic for think pieces, that I would not disgrace these hallowed pages with another trite contribution to the ouevre.

I am, however, duty-bound to note a recent development that suggests that remote depositions may not be long for this world. The issue arose before Judge Andrews last week in Takeda Pharms. USA, Inc. v. Mylan Pharms .Inc. C.A. No. 19-2216. The plaintiffs sought to depose the defendant's former counsel, who "purportedly reviewed, drafted, and edited the settlement and license agreements that are at the center of this …

View
Newer
Older

Archive